Last reviewed · How we verify
NCT04962399
Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
trial testing Enzyme linked immunosorbent assay in Diabetic Nephropathy Type 2 in 180 participants. Status unknown.
31 July 2022
Quick facts
| Lead sponsor | Zheng Guo |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 1 August 2021 |
| Primary completion | 31 July 2022 |
| Estimated completion | 31 October 2022 |
Drugs / interventions tested
- Enzyme linked immunosorbent assay
Conditions studied
- Diabetic Nephropathy Type 2 — all drugs for Diabetic Nephropathy Type 2 →
Sponsor
Zheng Guo
Who can join
Adults 18 to 65, any sex, with Diabetic Nephropathy Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, the early diagnosis ability of diabetic nephropathy (DKD) is relatively poor, leading to some missed diagnosis of early disease patients. At the same time, because DKD patients have complex metabolic disorders, once they develop to end-stage renal disease, compared with other renal diseases, the treatment of DKD is more difficult and the prognosis is poor. At present, the main treatment for DKD is to strengthen blood glucose control and control blood pressure through renin angiotensin aldosterone system (RAAS) to delay the occurrence and development of DKD, but it can not reduce the risk of most patients progressing to end-stage renal disease (ESRD). In recent years, it is becoming a new therapeutic target for DKD to control the inflammatory response by targeting the inflammatory factors and inflammatory signaling pathways. Therefore, this study attempts to explore the correlation between N / OFQ and the occurrence and development of type 2 DKD, and seek new theoretical basis for the potential treatment of inflammation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04962399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Enzyme linked immunosorbent assay
Trials testing the same drug.
- NCT05105165 — Regulatory Mechanism of Orphanin FQ in Patients With Chronic Ischemic Heart Failure · unknown
Other recruiting trials for Diabetic Nephropathy Type 2
Currently open trials in the same condition.
- NCT06586203 — Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes · NA · recruiting
- NCT05888909 — Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy · recruiting
- NCT06833541 — Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease · recruiting
- NCT04931537 — Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics. · recruiting
- NCT04573920 — Atrasentan in Patients With Proteinuric Glomerular Diseases · Phase 2 · active not recruiting
Other Zheng Guo trials
Trials by the same sponsor.
- NCT06732362 — To Observe the Clinical Effect of Femoral Nerve Block With Low Concentration of Ropivacaine Based on DPN Grading · not yet recruiting
- NCT06009055 — Effects of Remimazolam and Propofol on Anesthesia Induction · NA · unknown
- NCT05344794 — Relationship Between Serum N/OFQ and Brain-heart Syndrome · unknown
- NCT05619848 — Effect of Paravertebral Muscle Fat Infiltration on Rocuronium Use in Lumbar Surgery · EARLY_PHASE1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04962399 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zheng Guo
- Last refreshed: 15 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04962399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing